Objective: To observe the safety and efficacy of fecal microbiota transplantation (FMT) in treatment of Parkinson′s disease (PD) with constipation. Methods: From September 2017 to April 2019, 22 PD patients with serious constipation in the Department of Neurology, the Affiliated Huaian No. 1 People′s Hospital of Nanjing Medical University were treated with FMT and followed up for 12 weeks. Spontaneous bowel movement (SBM) per week and scores of Wexner Constipation Scale (Wexner), Constipation Quality of Life Scale (PAC-QOL) and Parkinson′s Disease Quality of Life Questionnaire (PDQ-39) were recorded before and after transplantation. Results: Compared with the number of independent defecation and scores before treatment, the number of independent defecation per week (4.63±2.25, 5.38±1.23, 5.75±1.29, 5.54±1.30 vs 1.57±0.74), Wexner score (7.92±2.61, 5.67±1.78, 5.08±1.83, 4.92±1.78 vs 16.67±4.31), PAC-QOL score (62.3±3.2, 58.8±2.8, 57.1±3.9, 59.6±4.4 vs 110.3±14.7) and PDQ-39 score (44.8±14.8, 37.8±12.8, 32.8±12.3, 31.9±9.2 vs 58.7±16.7) were significantly improved by FMT treatment at two, four, eight and 12 weeks (P<0.01). After 12-week treatment, the effective rate was 100% (22/22), and the clinical cure rate was 86% (19/22). No serious adverse reactions occurred during treatment. Conclusion FMT is effective and safe in treating PD with constipation.

Parkinson's disease (PD) is a common neurodegenerative disease in middle-aged and elderly people. Patients with PD often suffer from gastrointestinal symptoms in the early stage of the disease. Several studies have confirmed that gut microbiota is involved in the progress of PD. As one of the most effective ways to reconstruct the gut microbiota, fecal microbiota transplantation (FMT) has shown potential therapeutic effects on PD. This review summarizes the basic and clinical studies of FMT in the treatment of PD.
Aged ; Fecal Microbiota Transplantation ; Gastrointestinal Microbiome ; Humans ; Middle Aged ; Neurodegenerative Diseases ; Parkinson Disease/therapy*